Moreover, as the global
level, over the 300 million individuals are predicted to suffer from the
depression, which is equivalent to 4.4% of the world’s total populace. Furthermore,
the players in the market of antidepressant drugs is working more effectively while
spreading the awareness related to the applications of the antidepressant drugs
and providing effective treatments for the depression. According to the report
analysis, ‘Global
Antidepressant Drugs Market Forecast up to 2018 – 2024’ states that
there are several foremost players which presently functioning more effectively
for leading the fastest market growth and registering the high value of market
share across the globe while developing the technologies of production and
decreasing the prices of antidepressant drugs includes Novartis AG, Allergan
Inc., Elli Lilly and Company, AstraZeneca plc, GSK, Otsuka Holdings Co., Ltd.,
and Johnson & Johnson. The other protuberant players involve Pfizer,
Shionogi & Co. Ltd., Abbott Laboratories, Takeda Pharmaceutical Co., Ltd.,
and H. Lundbeck A/S.
Depression is a solemn
mental illness distressing more than 350 million people across the globe. This
is also acknowledged as the mainstream depression syndrome or unipolar
depression. According to a report by the Psychiatric Association, approximately
14.8 million adults in the US are anguish from the depression. Significant
increase in the aging populace and growing prevalence of the depression are the
general factors fueling the global antidepressant drugs market growth.
Compassionate initiatives from the government and several other organizations
and effective increase in the clinical trials will deliver an opportunity for
the market growth during the forecasted period.
The Government ingenuities
have been momentously transforming the market situation. Many of the initiatives
are taken to augment the consciousness and decrease the suicidal rate around
the globe. Depression is cramped by the mental health Gap Action Programme
(mhGAP) of the World Health Organization (WHO) to support the countries to augment
their conveniences for those misery from mental disorders, through distinctive support
by healthcare workers. A superior transitory is conventional by WHO for the handling
of depression. The corporations are motivating to improve an innovative drugs
to statement the unmet requirements in the market. For instance, in May 2018,
Esketamine Nasal Spray of the Janssen Pharmaceutical Corporations of Johnson
& Johnson demonstrated speedy advancements in the depressive indications in
patients with treatment-resistant depression in Phase III trials. Thus, this
drug is anticipated to be the one of the bestsellers in the market.
The global antidepressant
drugs market is predicted to observe a CAGR of 2.2% during the review period of
2018-2024. Based on the region, the global market of antidepressant is spread
across the globe which majorly involves North America, Europe, Asia Pacific,
and Rest of the World (ROW). North America accounts for the largest share of
the antidepressant drugs market, followed by Europe, Asia Pacific, and Rest of
the World. North America alone occupies more than 30% of the market, with a
significant contribution from the US to the market growth. Therefore, in the
coming years, it is predicted that the market of antidepressant drugs will
augment around the globe more positively over the forecasted period.
For more information on the research
report, refer to below link:
Contact Us:-
Ken
Research
Ankur
Gupta, Head Marketing & Communications
+91-9015378249
No comments:
Post a Comment